Infectious Disease

NIH study completes subject enrolment for Brii Biosciences’ Covid-19 antibodies

Brii Biosciences has announced that ACTIV-2 clinical trial of the National Institutes of Health (NIH) in the US closed enrolment for the Phase III part that will evaluate BRII-196 plus BRII-198 for Covid-19 treatment.

Dr. Reddy’s begins pilot of Russia’s Sputnik V vaccine in India

Dr. Reddy’s Laboratories has started a limited pilot of the Sputnik V Covid-19 vaccine, developed by Russian scientists, in India following regulatory authorisation from the Central Drugs Laboratory.

US FDA approves emergency use of Pfizer-BioNTech Covid-19 vaccine in adolescents

The US Food and Drug Administration (FDA) has expanded the emergency use authorisation (EUA) for Pfizer and BioNTech’s Covid-19 vaccine to include adolescents aged 12 to 15 years.

India’s DCGI allows use of oxygen dependence-lowering Covid-19 drug

The Drugs Controller General of India (DCGI) has granted emergency use authorisation for a new drug, 2-deoxy-D-glucose (2-DG), as adjunct therapy that can help lower supplemental oxygen dependence in moderate to severe Covid-19 patients.

Pfizer-BioNTech Covid-19 vaccine gets Canada approval for adolescents

Pfizer Canada and BioNTech have received Interim Order authorisation from Health Canada for the use of their Covid-19 vaccine in adolescents aged 12 to 15 years.

Johnson & Johnson to resume Covid-19 vaccine roll-out in Europe after EMA review

Johnson & Johnson (J&J) will resume Covid-19 vaccine roll-out in Europe following the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the overall benefit-risk profile being positive.

Airway Therapeutics’ IND application for AT-100 gets FDA acceptance to treat Covid-19

The US Food and Drug Administration (FDA) has approved Investigational New Drug (IND) application submitted by Airway Therapeutics to develop AT-100 (rhSP-D) for treating patients with Covid-19.

Anixa and OntoChem enter next stage of Covid-19 anti-viral therapy development

Biotechnology company Anixa Biosciences, partnered by IT and pharma solutions company OntoChem, has announced that it will enter the next stage of development of its potential anti-viral therapy for Covid-19.

US NIH-led study identifies SARS-CoV-2 virus infects cells in mouth

An international team led by researchers at the US National Institutes of Health (NIH) and the University of North Carolina at Chapel Hill have found that SARS-CoV-2 virus that causes Covid-19, infects cells in the mouth.